Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

3

Revenue 2017

MabThera/Rituxan

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. MabThera/Rituxan was produced by Roche.

WHO pilots scheme to make biosimilars available to poorer countries

WHO pilots scheme to make biosimilars available to poorer countries Plans to expand prequalification scheme to medicines such as Roche’s Rituxan and Herceptin. ... In the latest move the WHO says it will focus on biosimilar medicines, starting with Roche's widely-used cancer drugs MabThera/Rituxan (rituximab) and

A new decade of disruption: meeting the biosimilar challgenge

A new decade of disruption: meeting the biosimilar challgenge As the dust settles on the first ten years of disruption, the spotlight is now on the future as more leading MAbs, including Humira (adalimumab), MabThera (rituximab), Avastin (bevacizumab) and Lucentis

Mylan deal with Roche clears path to biosimilar Herceptin launch

Mylan deal with Roche clears path to biosimilar Herceptin launch Aside from Herceptin, and biosimilars of Roche's Avastin (bevacizumab) and Rituxan/MabThera (rituximab) are also starting to reach the market.

Mundipharma to launch first MabThera biosimilar in EU

Mundipharma to launch first MabThera biosimilar in EU The European Medicines Agency has approved MabThera (rituximab) biosimilar Truxima for use in all of the cancer blockbuster's licensed indications, becoming the first copycat of its kind to win regulatory ... Mundipharma. It showed comparable preclinical,

2016: The year when deal-makers took stock?

2016: The year when deal-makers took stock? Canada for biosimilar versions of Rituxan (rituximab) and Herceptin (trastuzumab). .

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics